Clinical Trial Update: Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating single-agent trastuzumab or lapatinib for HER2-overexpressing metastatic breast cancer. The trial status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Azienda Ospedaliera Ordine Mauriziano di Torino | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN